Literature DB >> 7586480

Chronic blepharitis: a review.

R E Smith1, C W Flowers.   

Abstract

Although blepharitis is one of the most common ocular disorders encountered in clinical practice, it may constitute a diagnostic and therapeutic enigma. Attempts to classify this disorder are difficult because of the complex mechanisms underlying its pathogenesis. Clinical and laboratory investigations have clearly established bacteria and meibomian gland abnormalities as major etiologic determinants. In addition, changes in tear film dynamics and underlying dermatologic abnormalities appear to contribute to pathogenesis. The clinical manifestations primarily occur along the lid margin, and the predominant symptoms are itching and burning. Currently there is no cure for this condition. In the case of staphylococcal blepharitis, for example, there is no long-term cure because patients are likely susceptible to the causative organism(s), and thus become reinfected. Therapy is aimed then at bringing the disease process under control. A therapeutic regimen consisting of lid hygiene, topical or systemic antibiotics, and tear replacement seems to be most effective in alleviating symptoms and maintaining disease control but requires prolonged treatment.

Entities:  

Mesh:

Year:  1995        PMID: 7586480

Source DB:  PubMed          Journal:  CLAO J        ISSN: 0733-8902


  16 in total

1.  Ophthaproblem. Chalazion.

Authors:  S Sharma
Journal:  Can Fam Physician       Date:  1998-06       Impact factor: 3.275

2.  Eyelid cleansing with ointment for obstructive meibomian gland dysfunction.

Authors:  Minako Kaido; Osama M A Ibrahim; Motoko Kawashima; Reiko Ishida; Enrique A Sato; Kazuo Tsubota
Journal:  Jpn J Ophthalmol       Date:  2016-10-03       Impact factor: 2.447

Review 3.  [Opinion of the BVA and the DOG on physical therapy of dry eye : July 2017 status].

Authors: 
Journal:  Ophthalmologe       Date:  2017-11       Impact factor: 1.059

4.  Azithromycin in DuraSite for the treatment of blepharitis.

Authors:  Jodi Luchs
Journal:  Clin Ophthalmol       Date:  2010-07-30

5.  [Meibomian glands : part III. Dysfunction - argument for a discrete disease entity and as an important cause of dry eye].

Authors:  E Knop; N Knop; H Brewitt; U Pleyer; P Rieck; B Seitz; F Schirra
Journal:  Ophthalmologe       Date:  2009-11       Impact factor: 1.059

6.  Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device.

Authors:  E Goto; Y Monden; Y Takano; A Mori; S Shimmura; J Shimazaki; K Tsubota
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

7.  Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study.

Authors:  J W Han; J S Yoon; S Y Jang
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

8.  Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis.

Authors:  Mehdi Zandian; Neda Rahimian; Sanaz Soheilifar
Journal:  Int J Ophthalmol       Date:  2016-07-18       Impact factor: 1.779

9.  A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis.

Authors:  Yazmin Yactayo-Miranda; Christopher N Ta; Lisa He; Thomas C Kreutzer; Martin M Nentwich; Anselm Kampik; Herminia Mino de Kaspar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-11       Impact factor: 3.117

10.  AzaSite® inhibits Staphylococcus aureus and coagulase-negative Staphylococcus biofilm formation in vitro.

Authors:  Eric C Wu; Regis P Kowalski; Eric G Romanowski; Francis S Mah; Y Jerold Gordon; Robert M Q Shanks
Journal:  J Ocul Pharmacol Ther       Date:  2010-10-28       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.